French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted by an earlier-than-anticipated start of the vaccination season. Quarterly business operating income,

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company reported third-quarter sales of 13.

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full-year earnings guidance. Read more here.

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.Most Read from BloombergRobotaxis Are No Friend of Public TransportationBooming Cambridge Exposes England’s Widening Wealth GapOman Sees an Urban Future Distinct From Dubai and Abu DhabiArgentina Drug Trafficking Hotspot Sees Murders PlungeClimate Change Is Killing Buildings in Slow MotionEarnings per share excluding some items reached €2.

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are raising alarms.

The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by earlier-than-anticipated flu and respiratory syncytial virus vaccine purchases.

Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial